Company: BIAF
Filing Date: 2025-09-30
Form Type: 8-K
Source: 0001493152-25-016366
Chunk: 2

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-09-30
Form: 8-K
Item: Item 8.01
Chunk 2
---
 Bid Price
Requirement for seven (7) consecutive trading days. In addition, the implementation of the reverse stock split is expected to eliminate
approximately $4 million in warrant-related derivate liabilities in the period ended September 30, 2025, which automatically converted
into stockholders’ equity upon the effectiveness of the reverse stock split.

As
previously reported in a Current Report on Form 8-K, on August 13, 2025, the Company and the holders
of certain warrants issued by the Company on May 7, 2025 (the “ May 2025 Warrants”) entered into amendments to the May 2025
Warrants (each, a “ Warrant Amendment”) pursuant to which certain provisions of the May 2025 Warrants that originally resulted
in liability treatment on the Company’s balance sheet as of June 30, 2025 were amended and restated. Following the Warrant Amendment,
the May 2025 Warrants are expected to be reclassified, which will result in an increase in stockholders’ equity of approximately
$2.8 million.

As
a result of the closing of the transaction described under Item 1.01 above as well as the transactions described under this Item 8.01,
the Company believes, as of the date of filing of this Current Report on form 8-K, that it has stockholders’ equity in excess of
$2,500,000, and has thereby regained compliance with the Continued Listing Equity Requirement.
The Company awaits Nasdaq’s confirmation of same.

Item
9.01 Financial Statements and Exhibits.